Estimation of the binding modes with important human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger components using molecular docking, computational, and pharmacokinetic modeling studies

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 841-866

  Qiu, Jia Xuan ^a,b   Zhou, Zhi Wei ^c   He, Zhi Xu ^d   Zhang, Xueji ^e   Zhou, Shu Feng ^c   Zhu, Shengrong ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b NANCHANG UNIVERSITY   (China)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d GUIZHOU MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF SCIENCE AND TECHNOLOGY BEIJING   (China)

Author keywords

CYP; Docking; Drug interaction; Drug metabolism; Ginger

Indexed keywords

(10) GINGEROL; (6) GINGEROL; 10 SHOGAOL; 6 GINGERDIONE; 6 SHOGAOL; 8 GINGEROL; 8 SHOGAOL; ARCURCUMENE; BETA BISABOLENE; BETA SESQUIPHELANDRENE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; METHYL 6 ISOGINGEROL; NIFEDIPINE; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG; WARFARIN; ZINGIBERENE; DRUG;

ARTICLE; BLOOD BRAIN BARRIER; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SOLUBILITY; ENZYME ACTIVATION; ENZYME BINDING; ENZYME INHIBITION; ENZYME REGULATION; HERB DRUG INTERACTION; HUMAN; IN VIVO STUDY; LIVER TOXICITY; MOLECULAR DOCKING; MOLECULAR INTERACTION; OPEN STUDY; PLASMA PROTEIN BINDING; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION; VALIDATION STUDY; ADVERSE EFFECTS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG INTERACTION; GINGER; METABOLISM; PHARMACOKINETICS;

BINDING SITES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; GINGER; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84923074000     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S74669     Document Type: Article

References (49)

1. De Smet PA. Herbal remedies. N Engl J Med. 2002;347(25): 2046–2056.
2. Chrubasik S, Pittler MH, Roufogalis BD. Zingiberis rhizoma: a comprehensive review on the ginger effect and efficacy profiles. Phytomedicine. 2005;12(9):684–701.
3. Kubra IR, Jaganmohanrao L. An overview on inventions related to ginger processing and products for food and pharmaceutical applications. Recent Patent Food, Nutr Agric. 2012;4(1):31–49.
4. Kubra IR, Rao LJ. An impression on current developments in the technology, chemistry, and biological activities of ginger (Zingiber officinale Roscoe). Crit Rev Food Sci Nutr. 2012;52(8):651–688.
5. Ali BH, Blunden G, Tanira MO, Nemmar A. Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research. Food Chem Toxicol. 2008;46(2):409–420.
6. Jolad SD, Lantz RC, Chen GJ, Bates RB, Timmermann BN. Commercially processed dry ginger (Zingiber officinale): composition and effects on LPS-stimulated PGE2 production. Phytochemistry. 2005;66(13):1614–1635.
7. Coon MJ. Cytochrome P450: nature’s most versatile biological catalyst. Annu Rev Pharmacol Toxicol. 2005;45:1–25.
8. Zhou SF, Xue CC, Yu XQ, Wang G. Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr Drug Metab. 2007;8(6):526–553.
9. Zhou SF, Zhou ZW, Li CG, et al. Identification of drugs that interact with herbs in drug development. Drug Discov Today. 2007;12(15–16):664–673.
10. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA. 1998;280(18):1569–1575.
11. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA. 2001;286(2):208–216.
12. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287(3):337–344.
13. Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs. 2005;65(9):1239–1282.
14. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–1205.
15. Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med. 2008;23(6):854–859.
16. Wang ZX, Sun J, Howell CE, et al. Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies. Fundam Clin Pharmacol. 2014;28(5):551–582.
17. Qiu JX, Zhou ZW, He ZX, et al. Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial to mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells. Drug Des Devel Ther. 2015;9:349–417.
18. Yin JJ, Sharma S, Shumyak SP, et al. Synthesis and biological evaluation of novel folic acid receptor-targeted, beta-cyclodextrin-based drug complexes for cancer treatment. PLoS One. 2013;8(5):e62289.
19. Ito K, Iwatsubo T, Kanamitsu S, et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev. 1998;50(3):387–412.
20. Zhou ZW, Zhou SF. Application of mechanism-based CYP inhibition for predicting drug-drug interactions. Expert Opin Drug Metab Toxicol. 2009;5(6):579–605.
21. Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci. 2001;58(5–6):737–747.
22. Lin JH. CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res. 2006;23(6):1089–1116.
23. Colalto C. Herbal interactions on absorption of drugs: mechanisms of action and clinical risk assessment. Pharmacol Res. 2010;62(3):207–227.
24. Kim IS, Kim SY, Yoo HH. Effects of an aqueous-ethanolic extract of ginger on cytochrome P450 enzyme-mediated drug metabolism. Pharmazie. 2012;67(12):1007–1009.
25. Kimura Y, Ito H, Hatano T. Effects of mace and nutmeg on human cytochrome P450 3A4 and 2C9 activity. Biol Pharm Bull. 2010;33(12):1977–1982.
26. Zhang W, Lim LY. Effects of spice constituents on P-glycoprotein-mediated transport and CYP3A4-mediated metabolism in vitro. Drug Metab Dispos. 2008;36(7):1283–1290.
27. Brandin H, Viitanen E, Myrberg O, Arvidsson AK. Effects of herbal medicinal products and food supplements on induction of CYP1A2, CYP3A4 and MDR1 in the human colon carcinoma cell line LS180. Phytother Res. 2007;21(3):239–244.
28. Chan E, Tan M, Xin J, Sudarsanam S, Johnson DE. Interactions between traditional Chinese medicines and Western therapeutics. Curr Opin Drug Discov Devel. 2010;13(1):50–65.
29. Saruwatari J, Nakagawa K, Shindo J, Nachi S, Echizen H, Ishizaki T. The in vivo effects of sho-saiko-to, a traditional Chinese herbal medicine, on two cytochrome P450 enzymes (1A2 and 3A) and xanthine oxidase in man. J Pharm Pharmacol. 2003;55(11):1553–1559.
30. Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006;2(6):875–894.
31. Chavez ML, Jordan MA, Chavez PI. Evidence-based drug herbal interactions. Life Sci. 2006;78(18):2146–2157.
32. Singh D, Gupta R, Saraf SA. Herbs-are they safe enough? An overview. Crit Rev Food Sci Nutr. 2012;52(10):876–898.
33. Chan E, McLachlan A, O’Reilly R, Rowland M. Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther. 1994;56(3):286–294.
34. Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS Jr. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol. 2001;41(7):715–722.
35. Chan E, McLachlan AJ, Pegg M, MacKay AD, Cole RB, Rowland M. Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol. 1994;37(6):563–569.
36. Jiang X, Williams KM, Liauw WS, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2005;59(4):425–432.
37. Funaki T, Soons PA, Guengerich FP, Breimer DD. In vivo oxidative cleavage of a pyridine-carboxylic acid ester metabolite of nifedipine. Biochem Pharmacol. 1989;38(23):4213–4216.
38. Young HY, Liao JC, Chang YS, Luo YL, Lu MC, Peng WH. Synergistic effect of ginger and nifedipine on human platelet aggregation: a study in hypertensive patients and normal volunteers. Am J Chin Med. 2006;34(4):545–551.
39. Dorso CR, Levin RI, Eldor A, Jaffe EA, Weksler BB. Chinese food and platelets. N Engl J Med. 1980;303(13):756–757.
40. Chiang HM, Chao PD, Hsiu SL, Wen KC, Tsai SY, Hou YC. Ginger significantly decreased the oral bioavailability of cyclosporine in rats. Am J Chin Med. 2006;34(5):845–855.
41. Zick SM, Djuric Z, Ruffin MT, et al. Pharmacokinetics of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol and conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev. 2008;17(8):1930–1936.
42. Yu Y, Zick S, Li X, Zou P, Wright B, Sun D. Examination of the pharmacokinetics of active ingredients of ginger in humans. AAPS J. 2011;13(3):417–426.
43. White B. Ginger: an overview. Am Fam Physician. 2007;75(11): 1689–1691.
44. Desai HG, Kalro RH, Choksi AP. Effect of ginger and garlic on DNA content of gastric aspirate. Indian J Med Res. 1990;92:139–141.
45. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009;69(13): 1777–1798.
46. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs. 2001;61(15):2163–2175.
47. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42(7):1017–1025.
48. Becker ML, Caspers PW, Kallewaard M, et al. Determinants of potential drug-drug interaction associated dispensing in community pharmacies in the Netherlands. Pharm World Sci. 2007;29(2):51–57.
49. De Smet PA. Clinical risk management of herb-drug interactions. Br J Clin Pharmacol. 2007;63(3):258–267.